GlassScriptPhysician profile
Charles M Sullivan
NPI 1144217530
$7,471.00
in general payments reported to CMS, 2019-2025
40 companies · $1,360 in 2025
The $1,360 reported for 2025 was more than what 91% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $830 · 2020: $155 · 2021: $83.06 · 2022: $1,544 · 2023: $1,601 · 2024: $1,898 · 2025: $1,360.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,834 · Education: $25.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,833.73 |
| Education | $25.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,663.03 | 2019-2025 | Ubrelvy, Vraylar, Qulipta |
| Novo Nordisk INC | $1,196.53 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,066.56 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $949.34 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $352.99 | 2019-2025 | |
| Amgen INC. | $300.74 | 2019-2025 | Evenity, Prolia, Prolia |
| Novartis Pharmaceuticals Corporation | $232.71 | 2019-2023 | |
| Abbott Laboratories | $201.73 | 2022-2025 | Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $175.69 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $149.58 | 2022-2024 | Xifaxan |
| Esperion Therapeutics, INC. | $141.56 | 2022-2025 | Nexletol |
| Eisai INC. | $102.57 | 2024-2025 | |
| Amarin Pharma, INC. | $84.53 | 2019-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $83.23 | 2022 | |
| Janssen Pharmaceuticals, INC | $75.61 | 2022 |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Currax Pharmaceuticals LLC | $66.79 | 2022-2023 | Contrave, Onzetra Xsail, Nexletol |
| Noven Therapeutics, LLC | $65.82 | 2024-2025 | Xelstrym |
| Xeris Pharmaceuticals, INC. | $60.34 | 2023-2024 | Keveyis |
| Dexcom, INC. | $49.09 | 2022-2025 | Dexcom G6 Transmitter |
| Takeda Pharmaceuticals U.S.A., INC. | $47.82 | 2019 | |
| Glaxosmithkline, LLC. | $46.52 | 2022-2024 | Shingrix, Arexvy |
| Idorsia Pharmaceuticals US INC | $44.05 | 2022-2023 | Quviviq |
| Arbor Pharmaceuticals, INC. | $36.34 | 2019 | |
| Antares Pharma, INC. | $33.22 | 2023-2025 | Xyosted, Tlando, Nocdurna |
| Nevro Corp. | $24.19 | 2024 | Senza |
| Bayer Healthcare Pharmaceuticals INC. | $20.55 | 2022 | |
| Phathom Pharmaceuticals, INC. | $20.00 | 2025 | Voquezna |
| Si-Bone, INC. | $19.32 | 2023 | |
| Jazz Pharmaceuticals INC. | $17.19 | 2022 | |
| Valencia Technologies Corporation | $15.95 | 2025 | Ecoin Device Kit |
| Otsuka America Pharmaceutical, INC. | $15.21 | 2025 | Rexulti |
| Ibsa Pharma INC. | $14.93 | 2025 | Tirosint, Flector, Licart |
| Amneal Pharmaceuticals LLC | $13.86 | 2025 | Unithroid |
| Exact Sciences Corporation | $13.32 | 2024 | Cologuard Collection Kit |
| Hologic Sales and Service, LLC | $12.97 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $12.77 | 2019 | |
| Circassia INC. | $11.69 | 2019 | |
| Merck Sharp & Dohme LLC | $11.36 | 2019 | |
| Allergan, INC. | $11.30 | 2020 | |
| Organon LLC | $10.00 | 2025 | Nexplanon |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Sullivan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.